1.Effect of weight reduction on the severity of lower urinary tract symptoms in obese male patients with benign prostatic hyperplasia: A randomized controlled trial.
Chi Hang YEE ; Wing Yee SO ; Sidney KH YIP ; Edwin WU ; Phyllis YAU ; Chi Fai NG
Korean Journal of Urology 2015;56(3):240-247
PURPOSE: We assessed whether weight reduction is an effective intervention for the management of lower urinary tract symptoms (LUTS) and investigated the relationship between obesity and LUTS. MATERIALS AND METHODS: This was a prospective randomized controlled trial that enrolled obese men older than 50 years with LUTS. The study period was 52 weeks. All patients received standardized alpha-adrenergic blocker therapy for the treatment of benign prostatic hyperplasia (BPH) during the run-in period. Patients were randomized to receive either a standardized prerecorded video program on the general principle of weight reduction or a comprehensive weight reduction program. Patients were assessed at different time points with symptom assessment, uroflowmetry, transrectal ultrasound, and metabolic assessment. RESULTS: Sixty-five patients were allocated to each study arm. After the study period, no significant difference in weight reduction was found between the two arms. When the pre- and postintervention parameters were compared, none were statistically different between the 2 arms, namely nocturia, International Prostate Symptom Score, quality of life assessment, and uroflowmetry parameters. When the whole study population was taken as a single cohort, these parameters were also not significantly different between the group with a body mass index of 25 to <30 kg/m2 and the group with a BMI of 30 to 35 kg/m2. CONCLUSIONS: We found no association between obesity and LUTS. This could have been due to the less marked weight difference in our cohort. Whereas weight reduction may be an effective measure to improve LUTS, the implementation of a successful program remains a challenge.
Adrenergic alpha-Antagonists/*therapeutic use
;
Aged
;
Body Mass Index
;
Humans
;
Lower Urinary Tract Symptoms/*drug therapy
;
Male
;
Middle Aged
;
*Obesity
;
Prospective Studies
;
Prostatic Hyperplasia/diagnosis/*drug therapy
;
Quality of Life
;
Severity of Illness Index
;
Treatment Outcome
;
*Weight Loss
2.Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review
Kai ZHANG ; Jeremy TEOH ; Gang ZHU ; Chi-Fai NG ; Michel SUBERVILLE ; Pilar LAGUNA ; Jean de la ROSETTE
The World Journal of Men's Health 2025;43(2):321-332
Purpose:
Irreversible electroporation (IRE) is a promising alternative treatment for low-intermediate-risk localized prostate cancer. In this systematic review we aim to evaluate the safety profile and functional and oncological outcomes of this new technique.
Materials and Methods:
A systematic review of the literature was performed on PubMed, EMBASE, and Scopus up to 24 August 2023. Nineteen studies were analyzed, including 12 prospective studies and 7 retrospective studies. A total of 1,452 patients underwent IRE as the sole primary treatment modality.
Results:
The in-field clinically significant prostate cancer rate was reported between 0%–15.6% in the repeat biopsy. The retreatment rate was reported from 8% to 36.6%. The 3 years failure-free survival was presented between 90%–96.8%. The post-operative pad-free rate ranged between 96.7%–100%. Greater heterogeneity exists considering the change in erectile function. The most common reported complications were urinary tract infection and hematuria. Major complications were rare.
Conclusions
These results underline that IRE achieves favorable oncological control with an excellent safety profile, in the meantime preserving patients’ urinary and erectile function
3.Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review
Kai ZHANG ; Jeremy TEOH ; Gang ZHU ; Chi-Fai NG ; Michel SUBERVILLE ; Pilar LAGUNA ; Jean de la ROSETTE
The World Journal of Men's Health 2025;43(2):321-332
Purpose:
Irreversible electroporation (IRE) is a promising alternative treatment for low-intermediate-risk localized prostate cancer. In this systematic review we aim to evaluate the safety profile and functional and oncological outcomes of this new technique.
Materials and Methods:
A systematic review of the literature was performed on PubMed, EMBASE, and Scopus up to 24 August 2023. Nineteen studies were analyzed, including 12 prospective studies and 7 retrospective studies. A total of 1,452 patients underwent IRE as the sole primary treatment modality.
Results:
The in-field clinically significant prostate cancer rate was reported between 0%–15.6% in the repeat biopsy. The retreatment rate was reported from 8% to 36.6%. The 3 years failure-free survival was presented between 90%–96.8%. The post-operative pad-free rate ranged between 96.7%–100%. Greater heterogeneity exists considering the change in erectile function. The most common reported complications were urinary tract infection and hematuria. Major complications were rare.
Conclusions
These results underline that IRE achieves favorable oncological control with an excellent safety profile, in the meantime preserving patients’ urinary and erectile function
4.Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review
Kai ZHANG ; Jeremy TEOH ; Gang ZHU ; Chi-Fai NG ; Michel SUBERVILLE ; Pilar LAGUNA ; Jean de la ROSETTE
The World Journal of Men's Health 2025;43(2):321-332
Purpose:
Irreversible electroporation (IRE) is a promising alternative treatment for low-intermediate-risk localized prostate cancer. In this systematic review we aim to evaluate the safety profile and functional and oncological outcomes of this new technique.
Materials and Methods:
A systematic review of the literature was performed on PubMed, EMBASE, and Scopus up to 24 August 2023. Nineteen studies were analyzed, including 12 prospective studies and 7 retrospective studies. A total of 1,452 patients underwent IRE as the sole primary treatment modality.
Results:
The in-field clinically significant prostate cancer rate was reported between 0%–15.6% in the repeat biopsy. The retreatment rate was reported from 8% to 36.6%. The 3 years failure-free survival was presented between 90%–96.8%. The post-operative pad-free rate ranged between 96.7%–100%. Greater heterogeneity exists considering the change in erectile function. The most common reported complications were urinary tract infection and hematuria. Major complications were rare.
Conclusions
These results underline that IRE achieves favorable oncological control with an excellent safety profile, in the meantime preserving patients’ urinary and erectile function
5.Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review
Kai ZHANG ; Jeremy TEOH ; Gang ZHU ; Chi-Fai NG ; Michel SUBERVILLE ; Pilar LAGUNA ; Jean de la ROSETTE
The World Journal of Men's Health 2025;43(2):321-332
Purpose:
Irreversible electroporation (IRE) is a promising alternative treatment for low-intermediate-risk localized prostate cancer. In this systematic review we aim to evaluate the safety profile and functional and oncological outcomes of this new technique.
Materials and Methods:
A systematic review of the literature was performed on PubMed, EMBASE, and Scopus up to 24 August 2023. Nineteen studies were analyzed, including 12 prospective studies and 7 retrospective studies. A total of 1,452 patients underwent IRE as the sole primary treatment modality.
Results:
The in-field clinically significant prostate cancer rate was reported between 0%–15.6% in the repeat biopsy. The retreatment rate was reported from 8% to 36.6%. The 3 years failure-free survival was presented between 90%–96.8%. The post-operative pad-free rate ranged between 96.7%–100%. Greater heterogeneity exists considering the change in erectile function. The most common reported complications were urinary tract infection and hematuria. Major complications were rare.
Conclusions
These results underline that IRE achieves favorable oncological control with an excellent safety profile, in the meantime preserving patients’ urinary and erectile function
6.Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review
Kai ZHANG ; Jeremy TEOH ; Gang ZHU ; Chi-Fai NG ; Michel SUBERVILLE ; Pilar LAGUNA ; Jean de la ROSETTE
The World Journal of Men's Health 2025;43(2):321-332
Purpose:
Irreversible electroporation (IRE) is a promising alternative treatment for low-intermediate-risk localized prostate cancer. In this systematic review we aim to evaluate the safety profile and functional and oncological outcomes of this new technique.
Materials and Methods:
A systematic review of the literature was performed on PubMed, EMBASE, and Scopus up to 24 August 2023. Nineteen studies were analyzed, including 12 prospective studies and 7 retrospective studies. A total of 1,452 patients underwent IRE as the sole primary treatment modality.
Results:
The in-field clinically significant prostate cancer rate was reported between 0%–15.6% in the repeat biopsy. The retreatment rate was reported from 8% to 36.6%. The 3 years failure-free survival was presented between 90%–96.8%. The post-operative pad-free rate ranged between 96.7%–100%. Greater heterogeneity exists considering the change in erectile function. The most common reported complications were urinary tract infection and hematuria. Major complications were rare.
Conclusions
These results underline that IRE achieves favorable oncological control with an excellent safety profile, in the meantime preserving patients’ urinary and erectile function
7.Identification of TPO receptors on central nervous system-a preliminary report.
Mo YANG ; Wen-Jie XIA ; Karen LI ; Nga-Hin PONG ; Ki-Wai CHIK ; Chi-Kong LI ; Margaret H L NG ; Ho-Keung NG ; Kwok-Pui FUNG ; Tai-Fai FOK
Journal of Experimental Hematology 2004;12(4):494-497
To identify the expression of thrombopoietin (TPO) receptors (c-mpl) on central nervous system (CNS) and to evaluate the role of TPO on neural cell proliferation and protection, immunohistochemical staining, RT-PCR, MTT, and annexin-V methods were used in this study. The results showed the expression of TPO receptor on human CNS and murine neural cells. C-mpl mRNA was identified in human cerebral hemispheres and cerebellum, and mouse neural cell line C17.2 by RT-PCR. C-mpl was also confirmed in human cerebral hemispheres by immunohistostaining with con-focal microscopy. Furthermore, TPO had a stimulating effect on the growth of in vitro neural cell C17.2 by MTT assay. The anti-apoptotic effect of TPO on C17.2 cells was also demonstrated by staining with annexin-V and PI. In conclusion, the first evidence showed the expression of TPO receptor c-mpl in central nervous system. Moreover, the effect of TPO on neural cell proliferation and anti-apoptosis was also demonstrated on in vitro neural cells.
Animals
;
Apoptosis
;
drug effects
;
Brain Chemistry
;
Cell Line
;
Cell Proliferation
;
drug effects
;
Erythropoietin
;
pharmacology
;
Humans
;
Mice
;
Neoplasm Proteins
;
analysis
;
Neurons
;
drug effects
;
Oncogene Proteins
;
analysis
;
Proto-Oncogene Proteins
;
analysis
;
Receptors, Cytokine
;
analysis
;
Receptors, Thrombopoietin
;
Thrombopoietin
;
pharmacology
8.Evaluation of the ClearVoice Strategy in Adults Using HiResolution Fidelity 120 Sound Processing.
Anna Chi Shan KAM ; Iris Hoi Yee NG ; Margaret Man Yi CHENG ; Terence Ka Cheong WONG ; Michael Chi Fai TONG
Clinical and Experimental Otorhinolaryngology 2012;5(Suppl 1):S89-S92
OBJECTIVES: This study aimed to evaluate the benefits of ClearVoice strategy on speech perception in noise and in everyday listening situations in Cantonese-speaking cochlear implant users. METHODS: Twelve experienced adult users of the Harmony implant and HiRes 120 sound processing participated in the study. The study employed a prospective within-subjects design wherein speech recognition in adults using HiRes 120 without ClearVoice turned on (control option) was compared to their performance with HiRes 120 with ClearVoice turned on. Each subject was evaluated with two different ClearVoice gain settings: -12 dB (ClearVoice medium) and -18 dB (ClearVoice high) after one-week of use. The Cantonese hearing in noise test and a questionnaire were used as the outcome measures. RESULTS: Subjects performed significantly better with ClearVoice medium than with control option in noise. No significant difference in performance was noted among the 3 settings in quiet. Most subjects reported high level of satisfaction with ClearVoice in daily listening situations and preferred to keep ClearVoice on. CONCLUSION: ClearVoice can help cochlear implant recipients to hear better in noise.
Adult
;
Cochlear Implantation
;
Cochlear Implants
;
Hearing
;
Humans
;
Noise
;
Prospective Studies
;
Speech Perception
;
Surveys and Questionnaires
9.Randomized controlled trial of antibiotic prophylaxis regimens for transrectal ultrasound-guided prostate biopsy.
Eddie Shu-Yin CHAN ; Ka-Lun LO ; Chi-Fai NG ; See-Ming HOU ; Sidney Kam-Hung YIP
Chinese Medical Journal 2012;125(14):2432-2435
BACKGROUNDA prior study showed significant antibiotic resistance to quinolone in our population. In this study we aimed to evaluate and compare the efficacy of a single versus a combined prophylactic antibiotic regimen before transrectal ultrasound-guided prostate biopsy (TRUGPB).
METHODSA prospective randomized study was conducted at a university hospital. Patients undergoing TRUGPB were randomized into an amoxicillin-clavulanate alone (1 mg; one dose before and two doses after biopsy) or an amoxicillin-clavulanate + ciprofloxacin group (250 mg; one dose before and two doses after biopsy). Patients were surveyed for infection symptoms by phone on days 3 and 30 after TRUGPB. We defined an infective complication as the occurrence of symptoms including fever, chills or rigor within 30 days after prostate biopsy, requiring medical treatment or hospitalization, aided by a territory-wide electronic medical record system.
RESULTSBetween November 2007 and July 2009, 367 patients were randomized to either amoxicillin-clavulanate alone or amoxicillin-clavulanate + ciprofloxacin group. The infection rates after TRUGPB were 3.91% in the former group (7 out of 179 patients) versus 0.53% (1 out of 188 patients) in the latter. Sixty-three percent (5/8) of patients with infective complications needed hospitalization. There was no intensive care unit admission or mortality during the study period.
CONCLUSIONSCombining prophylactic antibiotics with amoxicillin-clavulanate + ciprofloxacin significantly reduced the incidence of infective complications after TRUGPB. We recommended a combination regimen, especially in centre with high incidence of post-TRUGPB infection.
Amoxicillin ; therapeutic use ; Anti-Bacterial Agents ; therapeutic use ; Antibiotic Prophylaxis ; methods ; Biopsy, Needle ; adverse effects ; methods ; Ciprofloxacin ; therapeutic use ; Clavulanic Acid ; therapeutic use ; Humans ; Male ; Prostate ; diagnostic imaging ; pathology ; surgery ; Rectum ; Ultrasonography
10.The effect of renal cortical thickness on the treatment outcomes of kidney stones treated with shockwave lithotripsy.
Chi Fai NG ; Sylvia LUKE ; Peter K F CHIU ; Jeremy Y C TEOH ; Ka Tak WONG ; Simon S M HOU
Korean Journal of Urology 2015;56(5):379-385
PURPOSE: Because the shock wave passes through various body tissues before reaching the stone, stone composition may affect the treatment efficacy of shock wave lithotripsy (SWL). We investigated the effect of various tissue components along the shock wave path on the success of SWL. MATERIALS AND METHODS: From October 2008 to August 2010, a total of 206 patients with kidney stones sized 5 to 20 mm were prospectively recruited for a study of the factors that affect the outcome of treatment with a Sonolith Vision lithotripter. Successful SWL was defined as either stone-free status or residual fragments <4 mm at 12 weeks. Logistic regression analysis was performed to assess the factors that predicted treatment outcomes. Potential predictors included the patient's age, shock wave delivery rate, stone volume (SV), mean stone density (MSD), skin-to-stone distance (SSD), and the mean thickness of the three main components along the shock wave path: renal cortical thickness (KT), muscle thickness (MT), and soft-tissue thickness (ST). RESULTS: The mean age of the patients was 53.8 years (range, 25-82 years). The overall treatment success rate after one session of SWL was 43.2%. The mean KT, MT, and ST were 26.9, 16.6, and 40.8 mm, respectively. The logistic regression results showed that a slower shock wave delivery rate, smaller SV, a lower MSD, and a thicker KT were found to be significant predictors for successful SWL. SSD, MT, and ST were not predictors of successful treatment. CONCLUSIONS: Among the main tissue components along the shock wave path, a thicker KT was a favorable factor for successful SWL after adjustment for SV, MSD, and the shock wave delivery rate.
Adult
;
Aged
;
Aged, 80 and over
;
Female
;
Humans
;
Kidney Calculi/*therapy
;
Kidney Cortex/*radiography
;
*Lithotripsy
;
Logistic Models
;
Male
;
Middle Aged
;
Prospective Studies
;
Tomography, X-Ray Computed
;
Treatment Outcome